US Anticipates 100 Million People Vaccinated by February

Vaccine
  • By the end of February, the US plans to have vaccinated 100 million people against Covid-19, a top official said Wednesday, which is around 40 percent of the country’s adult population.
  • The move could begin within weeks when approval of the vaccines produced by Pfizer-BioNTech and Moderna-NIH is anticipated.
  • With the expansion of the production of both vaccines, 20 million will be reached in December, 30 million in January, and 50 million in February, with a total of 100 million.
  • Visit The Financial Today’s homepage for more stories.

WASHINGTON — By the end of February, the US plans to have vaccinated 100 million people against Covid-19, a top official said Wednesday, which is around 40 percent of the country’s adult population.

The move could begin within weeks when approval of the vaccines produced by Pfizer-BioNTech and Moderna-NIH is anticipated.

Two doses are required for both of these, the second after three weeks and four weeks, respectively.

“Between mid-December, and the end of February, we will have potentially immunized 100 million people,” Moncef Slauoi, scientific advisor to the government’s Operation Warp Speed (OWS) program, told reporters.

This will include the “at-risk” demographic, including the elderly, health care workers, and first responders, he added.

There would be an “ample” supply of vaccine to immunize three million long-term care facility patients, said the former pharmacy executive, who was appointed in May by President Donald Trump’s administration.

If states and other jurisdictions agree with federal proposals to prioritize this demographic, the remainder will be adequate to cover the majority of healthcare workers.

With the expansion of the production of both vaccines, 20 million will be reached in December, 30 million in January, and 50 million in February, with a total of 100 million.

However, this figure excludes other vaccines that are in the late stages of development by Johnson & Johnson and AstraZeneca-Oxford.

Between the end of December and mid-January, Slaoui said that both could deliver their results, paving the way for emergency authorization by February if the green light is granted by the US Food and Drug Administration (FDA).

Slaoui added that the AstraZeneca-Oxford vaccine might only be tested on the basis of a large US clinical trial involving 15,000 individuals and not on the findings from Britain and Brazil, where a dose error has marred the data.

Although Britain approved the Pfizer-BioNTech vaccine on Wednesday, the procedure is slower and more public in the United States.

Before a public meeting of the advisory committee takes place on December 10, the FDA will not issue an emergency use authorization (EUA). A similar meeting on the Moderna vaccine would take place on December 17.

Officials state the logistics are placed in motion to start delivering the vaccines almost instantly if authorized.

“When an EUA decision comes, distribution to the American people becomes immediate within 24 hours, that’s our goal,” said General Gus Perna, OWS Chief Operating Officer.

Right now, the first doses are expected to be distributed on December 15.

AFP contributed to this story.

Total
0
Shares

Leave a Reply

Previous Post
Amazon

Amazon in Discussions to Acquire Podcast Publisher Wondery

Next Post
NYSE

Chinese Companies Could Be Delisted From US Stock Markets

Related Posts